Sustained clinical benefit following systemic gene replacement therapy in Duchenne muscular dystrophy

Abstract

Sustained clinical benefit following systemic gene replacement therapy in Duchenne muscular dystrophyGene replacement therapy (GRT) is a rapidly developing therapeutic area. In late 2022, the American Society of Gene and Cell Therapy reported 2,031 gene therapies (i.e. GRT, RNA-or cell-therapy) at various